clinical trial · NCT04880876
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
AbbVie·phase3·enrolling by invitation·n = 124
Irritable Bowel Syndrome25mg Eluxadoline100mg Eluxadoline
brief summary
This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
started
Aug 13, 2021
primary completion
Dec 1, 2032
completion
Dec 1, 2032
last updated
Jul 17, 2025
official title
A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol